{"id":2049,"date":"2013-07-24T15:11:08","date_gmt":"2013-07-24T15:11:08","guid":{"rendered":"\/?p=2049"},"modified":"2013-07-24T15:11:48","modified_gmt":"2013-07-24T15:11:48","slug":"soligenix-inc-otcbbsngx-tumbles-on-its-way-up","status":"publish","type":"post","link":"\/articles\/soligenix-inc-otcbbsngx-tumbles-on-its-way-up\/","title":{"rendered":"Soligenix, Inc. (OTCBB:SNGX) Tumbles On Its Way Up"},"content":{"rendered":"

\"SNGXchart.png\"The biopharmaceutical company Soligenix, Inc. (OTCBB:SNGX<\/a>) was making a steep climb since last week. The stock managed to add half a dollar to its value for that short amount of time and at closing time on Monday was comfortably sitting on $1.60. Yesterday they took a tumble though and dropped by 7% to $1.49. <\/p>\n

The company has a diversified pipeline of products primarily focused on vaccines and “BioDefense” treatments for threats such as ricin and radiation. They have been making steady progress with their business plan that is concentrated on unmet medical needs. The company’s RiVax, a vaccine against ricin poisoning has received funding from both the FDA and NIH and has successfully passed two Phase 1 human trials.<\/p>\n

The Biomedical Advanced Research and Development Authority (BARDA) has shown acute interest in other product – OrbeShieldTM<\/sup>, used to treat gastrointestinal acute radiation syndrome. A response from BARDA is expected in the second half of 2013 on a proposed multy-year, multy-million dollar contract regarding the development of the drug. SNGX<\/a> have even more catalysts for the second half of 2013 with 3 different Phase 2 trials expected to be initiated.<\/p>\n

SNGX<\/a> finished the quarter ending March 31, with the following financials :<\/p>\n